Fulcrum Therapeutics Inc. (FULC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Fulcrum Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - FULC
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics, Inc.") (NASDAQ:FULC) concerning possible violations of federal securities laws. Fulcrum announced on September 12, 2024, that "its Phase 3 REACH trial evaluating losmapimod in patients with FSHD, did not achieve its primary endpoint of change from baseline in RSA with losmapimod compared to placebo.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc.(FULC) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESSWIRE / September 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ:FULC). Investors who purchased Fulcrum securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FULC.
Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 71% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know
Does Fulcrum Therapeutics, Inc. (FULC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know
Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 68.7% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Fulcrum Therapeutics, Inc. (FULC) Q2 2024 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q2 2024 Results Conference Call July 31, 2024 8:00 AM ET Company Participants Alex Sapir - CEO and President Alan Musso - CFO Iain Fraser - SVP of Early Development Conference Call Participants Corinne Johnson - Goldman Sachs Kristen Kluska - Cantor Fitzgerald Joseph Schwartz - Leerink Partners Dae Gon Ha - Stifel Gregory Renza - RBC Capital Markets Matthew Biegler - Oppenheimer Operator Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions].
